Healthy Skepticism Library

Items published in 2005

There are 1217 items in the Healthy Skepticism Library that were published in 2005.

Page 12 of 13 pages ‹ First  < 10 11 12 13 > 

HSL737
California prescription drug plan offers Canada-sized discounts
Bloomberg News 2005 Jan 6

HSL1198
Global Industry Position On Disclosure of Information About Clinical Trials
IFPMA 2005 Jan 6

HSL731
Rost P .
Contradicting itself on drug imports
The New Jersey Star-Ledger 2005 Jan 5

HSL732
Opera Singer Talks About Addiction
jointogether.org 2005 Jan 5

HSL733
Fuhrmann , M .
Health Canada defends drug-approval process, denies 'built-in bias'
Canadian Press 2005 Jan 5

HSL735
The ASSOCIATED.
Lilly Says Prozac Documents Contain No New Information
The New York Times 2005 Jan 5

HSL755
Vandehei , J .
Malpractice Bill Shields Drugmakers
THE WASHINGTON POST 2005 Jan 5

HSL729
Watkins , T .
Papers indicate firm knew possible Prozac suicide risk
CNN 2005 Jan 4

HSL728
Tsao A.
Big Changes for Big Pharma
Business Week 2005 Jan 3

HSL711
Konig , S .
Florida, Pfizer Team up to Improve Medicaid Patients' Use of Health Services
Health Care News 2005 Jan 1

HSL720
Belson , K .
Lilly Shares Fall on Report About Prozac Documents
THE NEW YORK TIMES 2005 Jan 1

HSL721
Bloomberg NEWS.
F.D.A. Approves Pfizer Remedy for Nerve Pain From Diabetes
The New York Times 2005 Jan 1

HSL2033
Mansfield PR, Mintzes B, Richards D, Toop L.
Direct to consumer advertising.
BMJ 2005 Jan 1; 330:(7481):5-6
http://bmj.bmjjournals.com/cgi/content/full/330/7481/5

HSL3792
Bloice C.
Why is this woman smiling? The hard sell of bad medicine.
Revolution 2005 Jan-Feb 01; 6:(1):22-9

HSL3804
Dalby AJ.
Reflections on the withdrawal of rofecoxib.
Cardiovasc J S Afr 2005 Jan-Feb 01; 16:(1):5-6
http://blues.sabinet.co.za/WebZ/Authorize?sessionid=0:autho=pubmed:password=pubmed2004&/AdvancedQuery?&format=F&next=images/ejour/cardio/cardio_v16_n1_a2.pdf

HSL5334
Frantz S.
How to avoid another 'Vioxx'.
Nat Rev Drug Discov 2005 Jan 01; 4:(1):5-7
http://www.nature.com/news/2004/041220/pf/nrd1629_pf.html

HSL1034
Lexchin JR.
Implications of pharmaceutical industry funding on clinical research.
Ann Pharmacother 2005 Jan; 39:(1):194-7
http://www.theannals.com/cgi/content/full/39/1/194

HSL1888
Hess R, Chang CC, Conigliaro J, McNeil M.
Understanding physicians' attitudes towards hormone therapy.
Womens Health Issues 2005 Jan-Feb; 15:(1):31-8
http://linkinghub.elsevier.com/retrieve/pii/S1049-3867(04)00103-3

HSL2072
Tibdewal S, Gupta M.
Mother's use of medication in their children of preschool age.
Indian J Public Health 2005 Jan-Mar; 49:(1):27-9

HSL2111
Meadows AB, Maine LL, Keyes EK, Pearson K, Finstuen K.
Pharmacy executive leadership issues and associated skills, knowledge, and abilities.
J Am Pharm Assoc (Wash DC) 2005 Jan-Feb; 45:(1):55-62

HSL4818
Granja M.
[Dangerous liaisons--physicians and pharmaceutical sales representatives].
Acta Med Port 2005 Jan-Feb; 18:(1):61-8
http://www.actamedicaportuguesa.com/pdf/2005-18/1/061-068.pdf

HSL4819
Brody H.
The company we keep: why physicians should refuse to see pharmaceutical representatives.
Ann Fam Med 2005 Jan-Feb; 3:(1):82-5
http://www.annfammed.org/cgi/content/full/3/1/82

HSL4952
Rataboli PV, Garg A.
Confusing brand names: nightmare of medical profession.
J Postgrad Med 2005 Jan-Mar; 51:(1):13-6
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3153&uid=15793332&db=PubMed&url=http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2005;volume=51;issue=1;spage=13;epage=16;aulast=Rataboli

HSL11092
Patten S, Cipriani A, Brambilla , P , Nose , M .
International Dosage Differences in Fluoxetine Clinical Trials
The Canadian Journal of Psychiatry 2005 Jan; 50:(1):31-38

HSL15162
Granja M.
LIGAÇÕES PERIGOSAS - Os Médicos e os Delegados de Informação Médica [DANGEROUS LIAISONS – physicians and pharmaceutical sales representatives]
Acta Med Port 2005 Jan-Feb; 18:(1):61-68
http://www.actamedicaportuguesa.com/pdf/2005-18/1/061-068.pdf

HSL19782
Pai S
Changing attitudes to drug company sponsorship?
Indian J Med Ethics 2005 Jan; 2:(1):
http://www.ijme.in/131le028.html

HSL3601
Chodock R, Yolkut D, Connolly DR.
"Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions
Tort Trial Insur Pract Law J 2005 Spr 01; 40:(3):997-1017

HSL5141
Lacasse JR.
Consumer advertising of psychiatric medications biases the public against nonpharmacological treatment.
Ethical Hum Psychol Psychiatry 2005 Fal 01; 7:(3):175-9

HSL19375
Zipkin DA, Steinman MA
Interactions between pharmaceutical representatives and doctors in training. A thematic review.
J Gen Intern Med 2005; (8):777-86
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490177/?tool=pubmed

HSL1552
United Kingdom: Companies and organizations in this country ranked by total spending
Lobby Watch - The Center for Public Integrity 2005;
http://www.publicintegrity.org/lobby/profile-pf.aspx?act=countries&year=2003&co=uk

HSL1605
Randall ML, Rosenbaum JR, Rohrbaugh RM, Rosenheck RA.
Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention.
Acad Psychiatry 2005 Spr; 29:(1):33-9
http://ap.psychiatryonline.org/cgi/content/abstract/29/1/33

HSL1647
Mohl PC.
Psychiatric training program engagement with the pharmaceutical industry: an educational issue, not strictly an ethical one.
Acad Psychiatry 2005 Sum; 29:(2):215-21
http://ap.psychiatryonline.org/cgi/content/full/29/2/215

HSL19043
Schwartz LM, Woloshin S, Welch HG
Can patients interpret health information? An assessment of the medical data interpretation test.
Med Decis Making 2005; 25:(3):290-300
http://mdm.sagepub.com/content/25/3/290.long

HSL2331
Muijrers P, Grol R., Sijbrandij J, Janknegt R., Knottnerus J
Differences in prescribing between general practitioners.
Unpublished 2005;

HSL3710
Bezold C, Peck J.
Drug regulation 2056.
Food Drug Law J 2005; 60:(2):127-36
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=pubmed

HSL3711
Zelenay JL Jr.
The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Food Drug Law J 2005; 60:(2):261-338

HSL3723
Manchanda P, Honka E.
The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review.
Yale J Health Policy Law Ethics 2005 Sum; 5:(2):785-822
http://www.ncbi.nlm.nih.gov/pubmed/16052900

HSL3724
Chin MH.
The patient's role in choice of medications: direct-to-consumer advertising and patient decision aids.
Yale J Health Policy Law Ethics 2005 Sum; 5:(2):771-84

HSL3725
Epstein RA.
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Yale J Health Policy Law Ethics 2005 Sum; 5:(2):741-70

HSL3726
Eisenberg RS.
The problem of new uses.
Yale J Health Policy Law Ethics 2005 Sum; 5:(2):717-39

HSL3747
Benezet JP.
[Pharmaceutical containers and their technological feature at the end of the middle ages].
J Pharm Belg 2005; 60:(2):64-75

HSL3754
Elliott C.
Adventure! Comedy! Tragedy! Robots! How bioethicists learned to stop worrying and embrace their inner cyborgs.
J Bioeth Inq 2005; 2:(1):18-23

HSL3782
Maynard A.
Quality control in the regulation of pharmaceuticals.
Pharmacoeconomics 2005; 23:(5):421-2

HSL3790
Malhi GS, Mitchell PB, Berk M, Goodwin GM.
Mood stabilizers: a labile label.
Acta Psychiatr Scand Suppl 2005; (426):5-6

HSL19042
Woloshin S, Schwartz LM.
Reducing the risk that patients get it wrong.
Gastroenterology 2005; 129:(2):748-50
http://www.gastrojournal.org/article/S0016-5085(05)01197-2/abstract

HSL4580
McCann MA.
Dietary supplement labeling: cognitive biases, market manipulation & consumer choice.
Am J Law Med 2005; 31:(2-3):215-68

HSL4591
Christenson V.
Drug companies offer major discounts to uninsured.
J Law Med Ethics 2005 Summer; 33:(2):399-403

HSL4592
Falit B.
Pharma's commitment to maintaining a clinical trial register: increased transparency or contrived public appeasement?
J Law Med Ethics 2005 Summer; 33:(2):391-6

HSL4596
Kahn JP.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Sum; 5:(3):W13
http://taylorandfrancis.metapress.com/(iiz3n4n1mkazbl45vc3o1i45)/app/home/contribution.asp?referrer=parent&backto=issue,31,34;journal,6,24;linkingpublicationresults,1:111605,1

HSL4597
Elliott C.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Summer; 5:(3):
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16006354&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=1526-5161&volume=5&issue=3&spage=W16

HSL4598
Andrews J.
U..S. Military sponsored vaccine trials and la resistance in Nepal.
Am J Bioeth 2005 Summer;5(3):W1-3 2005 Summer; 5:(3):W1-3
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16006352&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=1526-5161&volume=5&issue=3&spage=W1

HSL4706
Cain DM, Loewenstein G, Moore DA.
The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest
The Journal of Legal Studies 2005; 34:1-25
http://www.cbdr.cmu.edu/mpapers/CainLoewensteinMoore2005.pdf

HSL4718
Maurer W.
Creative and innovative statistics in clinical research and development.
Methods Inf Med 2005; 44:(4):551-60

HSL4719
Kagan J.
Human morality and temperament.
Nebr Symp Motiv 2005; 51:1-32

HSL4727
Arrieta J.
[Off label prescription in nephrology]
Nefrologia 2005; 25:(2):103-5

HSL4747
Johnston RE.
Academic science and the business of vaccines.
Arch Virol Suppl 2005; (19):203-6

HSL4748
Halpern GM.
COX-2 inhibitors: a story of greed, deception and death.
Inflammopharmacology 2005; 13:(4):419-25
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3152&uid=16354394&db=PubMed&url=http://openurl.ingenta.com/content/nlm?genre=article&issn=0925-4692&volume=13&issue=4&spage=419&aulast=Halpern

HSL4749
Abrahams E, Ginsburg GS, Silver M.
The Personalized Medicine Coalition: goals and strategies.
Am J Pharmacogenomics 2005; 5:(6):345-55

HSL4786
Castresana L, Mejia R, Aznar M.
[The attitude of physicians regarding the promotion strategies of the pharmaceutical industry].
Medicina (B Aires) 2005; 65:(3):247-51

HSL4797
Chandra A, Miller M.
A closer look at the concept, historical overview, and value of direct-to-consumer advertising of prescription drugs.
Hosp Top 2005 Fall; 83:(4):32-6

HSL4828
Stiles GM.
Wyeth responds to criticism.
Md Med 2005 Aut; 6:(4):5,

HSL4834
Tomes N.
The great American medicine show revisited
Bull Hist Med. 2005 Winter;79(4):627-63 2005 Wint; 79:(4):627-63
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3354&uid=16327082&db=PubMed&url=http://muse.jhu.edu/cgi-bin/resolve_openurl.cgi?issn=0007-5140&volume=79&issue=4&spage=627&aulast=Tomes

HSL4838
Klanica K.
Conflicts of interest in medical research: how much conflict should exceed legal boundaries?
J Biolaw Bus 2005; 8:(3):37-45

HSL4847
Polonuer JL.
[Strategies for drug promotion].
Medicina (B Aires) 2005; 65:(4):373-6

HSL4857
van Mosseveld C.
Pharmaceutical expenditure compared across countries.
Can J Clin Pharmacol 2005 Fal; 12:(3):e269-75
http://www.cjcp.ca/pdf/CJCP_04-048_e269.pdf

HSL4880
Longest BB Jr, Rohrer WM.
Communication between public health agencies and their external stakeholders.
J Health Hum Serv Adm 2005 Fal; 28:(2):189-217

HSL4927
Caulfield T.
Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues.
Health Law Rev 2005; 13:(2-3):114-6

HSL4928
Caulfield T.
Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.
Health Law Rev 2005; 13:(2-3):58-61

HSL4929
Lemmens T.
Federal regulation of REB review of clinical trials: a modest but easy step towards an accountable REB review structure in Canada.
Health Law Rev 2005; 13:(2-3):39-50

HSL4944
Regnstrom K, Burgess DJ.
Pharmacogenomics and its potential impact on drug and formulation development.
Crit Rev Ther Drug Carrier Syst 2005; 22:(5):465-92
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4847&uid=16313234&db=PubMed&url=http://www.begellhouse.com/journals/3667c4ae6e8fd136,0f80ebac03395679,22c907bb0f290242.html

HSL4988
Mastai R.
[Clinical practice and pharmaceutical industry: an always difficult relationship].
Acta Gastroenterol Latinoam 2005; 35:(4):209-10

HSL4992
Lau Y.
Is banning direct to consumer advertising of prescription medicine justified paternalism?
J Bioeth Inq 2005; 2:(2):69-74

HSL4993
Jordens C, Anderson L.
Should we be concerned about direct-to-consumer advertising of prescription drugs?
J Bioeth Inq 2005; 2:(2):61-2

HSL5098
Fernandez R, Gao C, Genkin W, Ghandi T, Graham R, Hou J, Hsu E, Hwang J.
Changing perspectives on dental advertising.
J Am Coll Dent 2005 Fall; 72:(3):24-6

HSL5099
Adamjee A, Alfi D, Agarwal D, Braithwaite Y, Chan J, Chey M, Cho H, Choi C.
What does the fact of advertising convey to patients?
J Am Coll Dent 2005 Fall; 72:(3):22-3

HSL5212
Cohen JG.
Recent developments in health law. Merck and the Vioxx decision: playing by the changing rules of the chemical exposure game
J Law Med Ethics 2005 Wint 00; 33:(4):866-9

HSL5238
Holbrook A, Grootendorst P, Willison D, Goldsmith C, Sebaldt R, Keshavjee K, Gaebel K.
Can current electronic systems meet drug safety and effectiveness requirements?
AMIA Annu Symp Proc 2005; 335-9

HSL5372
Regnier K, Kopelow M, Lane D, Alden E.
Accreditation for learning and change: quality and improvement as the outcome.
J Contin Educ Health Prof 2005 Sum; 25:(3):174-82
http://www3.interscience.wiley.com/cgi-bin/abstract/112093715/ABSTRACT?CRETRY=1&SRETRY=0

HSL5421
Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005; 28:110-1
http://www.australianprescriber.com/magazine/28/5/110/1/

HSL5439
Campo K, De Staebel O, Gijsbrechts E, van Waterschoot W.
Physicians' decision process for drug prescription and the impact of pharmaceutical marketing mix instruments.
Health Mark Q 2005; 22:(4):73-107

HSL5440
Macias W, Stavchansky Lewis L.
How well do direct-to-consumer, DTC, prescription drug web sites meet FDA guidelines and public policy concerns?
Health Mark Q 2005; 22:(4):45-71

HSL5441
Parker RS, Pettijohn CE.
Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians.
Health Mark Q 2005; 22:(4):27-43

HSL19040
Woloshin S, Schwartz LM, Welch HG
Patients and medical statistics. Interest, confidence, and ability.
J Gen Intern Med 2005; 20:(11):996-1000
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490265/?tool=pubmed

HSL5579
Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005; 183:(5):275-276
http://www.mja.com.au/public/issues/183_05_050905/letters_050905_fm-1.html

HSL5740
Curry TJ, Jarosch J, Pacholok , S.
Are Direct to Consumer Advertisements of Prescription Drugs Educational?: Comparing 1992 to 2002.
Journal of Drug Education 2005; 35:(3):217-232

HSL5753
Miller D .
Commentary: Psychologically Naive Assumptions about the Perils of Conflicts of Interest
Moore , D A, Cain , Dm , Loewenstein G. Conflicts of interest: Challenges and solutions in business, law, medicine, and public policy. New York, NY: Cambridge University Press 2005

HSL5784
Seamon MJ, Clauson KA.
Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
J Herb Pharmacother 2005; 5:(3):67-86

HSL5842
Lambert BL, Lin SJ, Tan H.
Designing safe drug names.
Drug Saf 2005; 28:(6):495-512

HSL7411
Gilad J, Moran L, Schlaeffer F, Borer A.
Antibiotic drug advertising in medical journals.
Scand J Infect Dis 2005; 37:(11-12):910-2
http://www.ncbi.nlm.nih.gov/pubmed/16308229

HSL8777
Singh AR, Singh SA.
The connection between academia and industry
Mens Sana Monographs 2005; 3:(1):5-35
http://www.msmonographs.org/article.asp?issn=0973-1229;year=2005;volume=3;issue=1;spage=5;epage=35;aulast=Singh

HSL8778
Singh AR, Singh SA.
Public welfare agenda or corporate research agenda?
Mens Sana Monographs 2005; 3:(1):41-80
http://www.msmonographs.org/article.asp?issn=0973-1229;year=2005;volume=3;issue=1;spage=41;epage=80;aulast=Singh

HSL8824
Kassirer JP.
On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health
New York: Oxford University Press, USA 2005
http://www.oup.com/us/catalog/general/subject/Economics/Health/?view=usa&ci=9780195300048

HSL8825
Abramson J.
Overdosed America: The Broken Promise of American Medicine
New York: Harper Collins 2005
http://www.harpercollins.com/books/9780060568535/Overdosed_America/index.aspx

HSL8826
Moynihan R, Cassels A.
Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients
New York: Nation Books 2005
http://web.archive.org/web/20070416141611/http://www.nationbooks.org/book.mhtml?t=sickness

HSL8994
Moore DA, Cain DM, Loewenstein G, Bazerman MH.
Conflicts of Interest: Challenges and Solutions in Business, Law, Medicine, and Public Policy
New York: Cambridge University Press 2005
http://www.cambridge.org/catalogue/catalogue.asp?isbn=9780511128370&ss=fro

HSL19377
Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis
OHRI 2005
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

HSL9987
Lexchin J.
Intellectual propety rights and the Canadian pharmaceutical marketplace: Where do we go from here?
International Journal of Health Services 2005; 35:(2):237 - 256
http://baywood.metapress.com/(iurdbb45zrns2y55w4i3yn45)/app/home/contribution.asp?referrer=parent&backto=issue,2,13;journal,9,146;linkingpublicationresults,1:300313,1

HSL9988
Mintzes B, Lexchin J.
Do higher drug costs lead to better health?
Can J Clin Pharmacol 2005 Win; 12:(1):e22-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16055941&query_hl=8&itool=pubmed_DocSum

HSL10299
Narhi U, Vanakoski J, Sihvo S.
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects.
Clin Drug Investig 2005; 25:(4):243-8
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17523774

HSL12608
Harp TN, McKenna M, Shute N.
Media, law, and the public's health.
J Law Med Ethics 2005 Win; 33:(4):
http://www.ncbi.nlm.nih.gov/pubmed/16689163?dopt=Abstract

Page 12 of 13 pages ‹ First  < 10 11 12 13 >